Search Results for "meal b"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for meal b. Results 21 to 26 of 26 total matches.

Drugs for Cognitive Loss and Dementia

   
The Medical Letter on Drugs and Therapeutics • Aug 22, 2022  (Issue 1657)
. 4. Maximum dose of transdermal donepezil is 10 mg/day. 5. Taken with meals. 6. In patients ...
Alzheimer's disease (AD) is the most common cause of dementia, but cognitive decline is also associated with other neurological conditions such as Parkinson's disease, dementia with Lewy bodies, vascular dementia, and frontotemporal dementia.
Med Lett Drugs Ther. 2022 Aug 22;64(1657):129-36 |  Show IntroductionHide Introduction

Drugs for Chronic Heart Failure

   
The Medical Letter on Drugs and Therapeutics • May 26, 2025  (Issue 1729)
, moderate hepatic impairment (Child-Pugh B), or hypotension. The dosage of sacubitril/valsartan should ...
Pharmacologic management of chronic heart failure (HF) is primarily determined by the patient's left ventricular ejection fraction (LVEF) and severity of symptoms. Patients with chronic HF who have an LVEF ≤40% are considered to have heart failure with reduced ejection fraction (HFrEF) and those with an LVEF ≥50% are considered to have heart failure with preserved ejection fraction (HFpEF). Patients with an LVEF of 41-49% have heart failure with mildly reduced or mid-range ejection fraction.
Med Lett Drugs Ther. 2025 May 26;67(1729):81-8   doi:10.58347/tml.2025.1729a |  Show IntroductionHide Introduction

Treatment of Atrial Fibrillation

   
The Medical Letter on Drugs and Therapeutics • Jan 08, 2024  (Issue 1693)
impairment (Child-Pugh B or C) Dose adjustment required for renal impairment 542.50 1. Approximate WAC ...
Atrial fibrillation (AF) is the most common arrhythmia in the world. Risk factor modification, anticoagulation, rhythm control, and rate control are the four pillars of its management. American College of Cardiology/American Heart Association (ACC/AHA) guidelines on management of AF were updated recently.
Med Lett Drugs Ther. 2024 Jan 8;66(1693):1-8   doi:10.58347/tml.2024.1693a |  Show IntroductionHide Introduction

Drugs for Epilepsy

   
The Medical Letter on Drugs and Therapeutics • Aug 05, 2024  (Issue 1708)
leukocyte antigen (HLA)-B*1502 allele, which occurs almost exclusively in Asians.55 The FDA has recommended ...
When used for the appropriate seizure type, antiseizure medications (ASMs) are roughly equivalent in efficacy. In addition to the seizure type, the choice of drug is usually based on factors such as ease of use, spectrum of activity, adverse effects, interactions with other drugs, presence of comorbid conditions, suitability for elderly persons and those with childbearing potential, and cost. Treatment should begin with a single drug, increasing the dosage gradually until seizures are controlled or adverse effects become unacceptable. If seizures persist, expert clinicians generally...
Med Lett Drugs Ther. 2024 Aug 5;66(1708):121-8   doi:10.58347/tml.2024.1708a |  Show IntroductionHide Introduction

Drugs for Sexually Transmitted Infections

   
The Medical Letter on Drugs and Therapeutics • Jun 27, 2022  (Issue 1653)
to be established; animal studies have shown adverse effects on the fetus. Taking ivermectin with a meal increases ...
This article includes recommendations for management of most sexually transmitted infections (STIs) other than HIV and viral hepatitis. Some of the indications and dosages recommended here have not been approved by the FDA (see Table 1).
Med Lett Drugs Ther. 2022 Jun 27;64(1653):97-104 |  Show IntroductionHide Introduction

Comparison Table: Some Oral Antiseizure Medications (online only)

   
The Medical Letter on Drugs and Therapeutics • Aug 05, 2024  (Issue 1708)
Patients with HLA-B*1502 allele are at greater risk for severe skin reactions; Asian patients should ...
View the Comparison Table: Some Oral Antiseizure Medications
Med Lett Drugs Ther. 2024 Aug 5;66(1708):e133-40   doi:10.58347/tml.2024.1708b |  Show IntroductionHide Introduction